Pharmacoepidemiological profiles of oral hypoglycemic agents among 28,773 Chinese patients with diabetes

Diabetes Research and Clinical Practice

Volumn 96, Issue 3, 2012, Pages 319-325

  Wong, Martin C S ^a   Kong, Alice P S ^a   So, W Y ^a   Tse, Shelly L A ^a   Wang, Harry H X ^a   Jiang, Johnny Y ^b   Chan, Juliana C N ^a   Griffiths, Sian M ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Associated factors; Chinese; Discontinuation; Oral hypoglycemic agents

Indexed keywords

ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CHINESE; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HONG KONG; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; PATIENT COMPLIANCE; PHARMACOEPIDEMIOLOGY; SOCIOECONOMICS;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HONG KONG; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT SELECTION; PHARMACOEPIDEMIOLOGY; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SOCIOECONOMIC FACTORS; WITHHOLDING TREATMENT;

EID: 84862785539     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.01.012     Document Type: Article

References (37)

1. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
2. Centre for Disease Control and Prevention. 2007 National Diabetes Fact Sheet. Available at: ; 2011 [accessed 23.12.2011]. http://www.cdc.gov/diabetes/pubs/factsheet07.htm.
3. Castell C., Tresserras R., Serra J., Goday A., Lloveras G., Salleras L. Prevalence of diabetes in Catalonia (Spain): an oral glucose tolerance test-based population study. Diabetes Res Clin Pract 1999, 43:33-40.
4. Lopatynski J., Mardarowicz G., Nicer T., Szczesniak G., Krol H., Matej A., et al. The prevalence of type II diabetes mellitus in rural urban population over 35 years of age in Lublin region (Eastern Poland). Pol Arch Med Wewn 2001, 106:781-786.
5. Simmons D., Williams D.R., Powell M.J. The Coventry Diabetes Study: prevalence of diabetes and impaired glucose tolerance in Europids and Asians. Q J Med 1991, 81:1021-1030.
6. Diabetes Statistics American Diabetes Association. Available at: ; 2011 [accessed on 23.12.2011]. http://www.diabetes.org/diabetes-basics/diabetes-statistics/%3Floc=DropDownDB-stats.
7. International Diabetes Federation Diabetes Atlas. The Global Burden. Available at: ; 2011 [accessed on 23.12.2011]. http://www.idf.org/diabetesatlas/5e/the-global-burden.
8. Garber A.J., Duncan T.G., Goodman A.M., Mills D.J., Rohlf J.L. Efficacy of metformin in type II diabetes: results of a double-blind placebo-controlled, dose response trial. Am J Med 1997, 103:491-497.
9. Grant P.J. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care 1996, 19:64-66.
10. DeFronzo R.A., Goodman A.M. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995, 333:541-549.
11. Tessier D., Maheux P., Khalil A., Fulop T. Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Metabolism 1999, 48:897-903.
12. Hermann L.S., Schersten B., Bitzen O., Kjellstrom T., Lindgarde F., Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994, 17:1100-1109.
13. Ho P.M., Rumsfeld J.S., Masoudi F.A., McClure D.L., Plomondon M.E., Steiner J.F., et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006, 166:1836-1841.
14. Lipska K.J., Wang Y., Kosiborod M., Masoudi F.A., Havranek E.P., Krumholz H.M., et al. Discontinuation of antihyperglycemic therapy and clinical outcomes after acute myocardial infarction in older patients with diabetes. Circ Cardiovasc Qual Outcomes 2010, 3:236-242.
15. Lamberts E.J., Nijpels G., Welschen L.M., Hugtenburg J.G., Dekker J.M., Souverein P.C., et al. Long term patterns of use after initiation of oral antidiabetic drug therapy. Pharmacoepidemiol Drug Saf 2010, 10.1002/pds.2089.
16. M.C. Wong, A.P.S. Kong, W.Y. So, J.Y. Jiang, J.C.N. Chan, S.M. Griffiths, Adherence to oral hypoglycemic agents in 26,782 Chinese patients: a cohort study. J Clin Pharmacol. doi:10.1177/0091270010382911.
17. Wong M.C.S., Jiang J.Y., Griffiths S. Factors associated with switching of antihypertensive drugs among 93,286 Chinese patients: a cohort study. J Hum Hypertens 2010, 24:669-677.
18. Wong M.C.S., Jiang J.Y., Lam A.T., Fung H., Griffiths S., Mercer S.W. Health services research in the public healthcare system in Hong Kong: an analysis of over 1 million antihypertensive prescriptions between 2004 and 2007 as an example of the potential and pitfalls of using routinely collected electronic patient data. BMC Health Serv Res 2008, 8:138.
19. Wong M.C.S., Jiang J.Y., Lam A.T., Fung H., Griffiths S., Mercer S.W. Patterns of antihypertensive prescribing, discontinuation and switching among a Hong Kong Chinese population from over one million prescriptions. J Hum Hypertens 2008, 22:714-716.
20. Wong M.C.S., Jiang J.Y., Gibbs T., Griffiths S.M. Factors associated with antihypertensive drug discontinuation among Chinese patients: a cohort study. Am J Hypertens 2009, 22:802-810.
21. Wong M.C.S. Short- and long-term discontinuation patterns of commonly prescribed antihypertensive drugs among a Chinese population: cohort study. J Hum Hypertens 2008, 22:435-437.
22. HA and clinical research - Support, Output and Direction. Available at ; 2011 [accessed 26.07.2011]. http://www.ha.org.hk/ho/research_ethics/msdc_p181.pdf.
23. Population census 2006. Hong Kong Special Administrative Region, China. Available at ; 2011 [accessed 26.07.2011]. http://www.bycensus2006.gov.hk/en/index.htm.
24. MacDonald T.M., Morant S.V., Mozaffari E. Drug treatment discontinuation and achievement of target blood pressure and cholesterol in United Kingdom primary care. Curr Med Res Opin 2007, 23:2765-2774.
25. Boccuzzi S.J., Boccuzzi S.J., Wogen J., Fox J., Sung J.C., Shah A.B., et al. Utilization of oral hypoglycemic agents in a drug-insured US population. Diabetes Care 2001, 24:1411-1415.
26. Dailey G., Kim M.S., Lian J.F. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a Medicaid patient population with type 2 diabetes mellitus. Clin Ther 2001, 23:1311-1320.
27. Cramer J.A., Benedict A., Muszbek N., Keskinaslan A., Khan Z.M. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidemia: a review. Int J Clin Pract 2008, 62:76-87.
28. Hertz R.P., Unger A.N., Lustik M.S. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study for adults with employer-sponsored health insurance. Clin Ther 2005, 27:1064-1073.
29. Chodick G., Shalev V., Gerber Y., Heymann A.D., Silber H., Simah V., et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008, 30:2167-2179.
30. Rasmussen I.N., Glslason G.H., Rasmussen S., Abildstrom S.Z., Schramm T.K., Køber L., et al. Use of statins and beta-blockers after acute myocardial infarction according to income and education. J Epidemiol Community Health 2007, 61:1091-1097.
31. Billups S.J., Malone D.C., Carter B.L. The relationship between drug therapy noncompliance and patient characteristics, health-related quality of life, and health care costs. Pharmacotherapy 2000, 20:941-949.
32. Caro J.J., Salas M., Speckman J.L., Raggio G., Jackson J.D. Persistence with treatment for hypertension in actual practice. CMAJ 1999, 160:31-37.
33. Knight E.L., Bohn R.L., Wang P.S., Glynn R.J., Mogun H., Avorn J. Predictors of uncontrolled hypertension in ambulatory patients. Hypertension 2001, 38:809-814.
34. Stephens J.M., Blak B.T., Gold K.F. Persistence patterns with oral hypoglycemic agents in type 2 diabetes. J Clin Outcomes Manage 2002, 9:491-499.
35. Sclar D.A., Robison L.M., Skaer T.L., Dickson W.M., Kozma C.M., Reeder C.E. Sulfonylurea pharmacotherapy regimen adherence in a Medicaid population: influence of age, gender, and race. Diabetes Educ 1999, 25:531-538.
36. Venturini F., Nichol M.B., Sung J.C., Bailey K.L., Cody M., McCombs J.S. Compliance with sulfonylureas in a health maintenance organization: a pharmacy record-based study. Ann Pharmacother 1999, 33:281-288.
37. Donnan P.T., MacDonald T.M., Morris A.D. Adherence to prescribed oral hypoglycemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med 2002, 19:279-284.